Αποτελέσματα Αναζήτησης
1 Σεπ 2022 · Key Points. IgD myeloma was historically associated with worse outcomes, but we now report a standard cytogenetic risk profile and survival outcomes. Improved IgD myeloma survival is due to earlier diagnosis, improved supportive care, and response to novel antimyeloma therapies.
New drugs such as bortezomib and the immune-modulating drugs, as well as ASCT, may improve the outcomes of patients with IgD MM. New treatment strategies that aim to induce high-quality responses before ASCT and maintain the response after ASCT may be needed to improve the outcomes of such patients.
20 Οκτ 2022 · We discuss the biology of IgD multiple myeloma, the need for prospective studies, and challenges for improvements in diagnosis and treatment. We suggest an International Register to accelerate development of best practice guidelines for diagnosis, risk stratification, and treatment.
IgD has antibody activity to specific antigens (34, 53, 60, 109, 110); individuals with high levels of IgD can produce specific IgD antibodies after antigenic challenge .
17 Ιουλ 2019 · Objective: Immunoglobulin D (IgD) levels are often elevated in patients with autoimmune diseases. However, the oncogenic activities of IgD and IgD receptor (IgDR) in diffuse large B-cell lymphoma (DLBCL) have not been reported in detail.
1 Αυγ 2024 · Immunoglobulin M (IgM) antibodies are located in the blood and fluid of the lymph system (network of tubes and organs that helps remove foreign substances and waste). These antibodies are the first responders and help “remember” previous infections and foreign invaders.
Activations of immune responses via mIgD-BCR or sIgD by specific antigens or anti-IgD antibody thereby produce a broad and complex mix of cellular, antibody and cytokine responses from both the innate and adaptive immune systems.
